Phillip W. Iversen

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau et al. · Molecular Cancer Therapeutics · 2014 · 101 citations · Full text

Medicine, Cancer Biology, Oncology +13

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Jian Du, Lei Yan, Raquel Torres et al. · Molecular Cancer Therapeutics · 2019 · 52 citations · Full text

Medicine, Oncology, Pharmacology +15

Mechanism of Action Assays for Enzymes

John Strelow, Walthère Dewé, Phillip W. Iversen et al. · 2012 · 50 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Assay Operations for SAR Support

Benoît Beck, Yunfei Chen, Walthere Dere et al. · Europe PMC (PubMed Central) · 2012 · 26 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Molecular Cancer Therapeutics · 2011 · 15 citations

Medicine, Oncology, Pharmacology +17